Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Respiratory Syncytial Virus Therapeutics Market

Respiratory Syncytial Virus Therapeutics Market Share

Report ID: GMI9184
Published Date: Apr 2024
Report Format: PDF

Download Free Sample

Respiratory Syncytial Virus Therapeutics Market Share

The respiratory syncytial virus therapeutics industry is characterized by the presence of several key players offering innovative products. The strategic partnerships, mergers, and acquisitions are common strategies employed by players to expand their market presence, enhance their service portfolios, and gain a competitive advantage.

Respiratory Syncytial Virus Therapeutics Market Companies

Prominent players operating in the industry include:

AbbVie Inc.
AstraZeneca PLC
Bausch Health Companies Inc.
Gilead Sciences
GSK plc
Johnson & Johnson
Medivir AB
Merck & Co., Inc
Pfizer Inc.
Sanofi

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Market size for respiratory syncytial virus therapeutics was USD 5.8 billion in 2023 and is expected to register 12.8% CAGR from 2024-2032 owing to the ongoing advancements in treatment, rising disease burden, growing aging population, and increased early childhood healthcare worldwide.

Respiratory syncytial virus therapeutics industry from the palivizumab segment recorded USD 3.3 billion in 2023 and is expected to register an appreciable CAGR from 2024-2032 due to its high efficacy in preventing severe RSV infections in high-risk populations.

North America industry is expected to register 12.7% CAGR from 2024-2032 due to the presence of advanced healthcare infrastructure, including well-equipped hospitals, healthcare facilities, and research institutions in the region.

AbbVie Inc., AstraZeneca PLC, Bausch Health Companies Inc., Gilead Sciences, GSK plc, Johnson & Johnson, Medivir AB, Merck & Co., Inc, Pfizer Inc., and Sanofi, are some of the major respiratory syncytial virus therapeutics companies worldwide.